A 63-year-old woman with long-standing type 2 diabetes (HbA1c 8.5%), hypertension and a prior NSTEMI is on maximal metformin and an ACE inhibitor. eGFR is 55 mL/min/1.73 m² and urinary albumin-to-creatinine ratio is 12 mg/mmol. According to Diabetes Canada, which additional antihyperglycaemic agent is preferred to reduce her cardiovascular risk?